Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European Commission for anti-competitive practices related to its blockbuster multiple sclerosis drug, Copaxone. The fine marks one of the largest penalties imposed on a pharmaceutical company for breaching antitrust regulations in recent years, surpassing the penalty imposed on […]
In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine), along with related assets, from Acorda Therapeutics, Inc. This transaction, valued at USD 185 million in cash, was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code, […]
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 inhibitor, NB-4746. This first-in-class, oral, brain-penetrating inhibitor offers broad therapeutic potential across a range of neurological conditions, including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Traumatic Brain Injury (TBI), and […]
India-based Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Inc., USA has introduced its Fingolimod Capsules, 0.5 mg in the US market. The product is the generic version of Gilenya Capsules, 0.5 mg, a multiple sclerosis drug from Novartis Pharmaceuticals. Sanjeev Krishan — Glenmark North America President said: “We are very pleased to bring to […]
Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), in a deal that values the combined entity at around $1 billion. Through the deal, Akili Interactive will become a publicly-listed company with a listing on Nasdaq under the “AKLI” […]
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) for the treatment of relapsing forms of multiple sclerosis (RMS). The approval is for the use of the anti-CD20 monoclonal antibody (mAb) as a subcutaneous injection in clinically isolated syndrome, […]
Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen’s Tecfidera patent U.S. Patent No. 8,399,514 for lack of written description. According to the company, the 8,399,514 patent claimed methods for the treatment of multiple sclerosis (MS) with a dose of 480 mg/day of dimethyl […]
Ponesimod OPTIMUM trial results : Johnson & Johnson’s Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to Aubagio (teriflunomide) in adults having relapsing multiple sclerosis (MS). The OPTIMUM clinical trial, which enrolled 1,133 participants, assessed the efficacy and safety of the selective sphingosine-1-phosphate receptor 1 (S1P1) modulator […]
US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]
If people with multiple sclerosis consume 290 calories of soda or sugar sweetened beverages a day, their symptoms may worsen as warned by the researchers. Multiple Sclerosis is a progressive and a degenerative disease in which the immune system attacks nerves resulting in many neurological symptoms. As per the study, it is revealed that people […]